|1.||Liu, L M: 4 articles (12/2000 - 06/2000)|
|2.||Chen, H S: 4 articles (12/2000 - 06/2000)|
|3.||Lu, R Q: 4 articles (12/2000 - 06/2000)|
|4.||Hu, D Y: 3 articles (09/2000 - 06/2000)|
|5.||Nan, X: 2 articles (12/2000 - 06/2000)|
|6.||Ming, M J: 2 articles (12/2000 - 06/2000)|
|7.||Mei, J M: 2 articles (09/2000 - 09/2000)|
|8.||Xiao, N: 2 articles (09/2000 - 09/2000)|
|9.||Chen, H H: 2 articles (09/2000 - 09/2000)|
|10.||Yang, Guangming: 1 article (06/2006)|
04/01/1987 - "The potent cardiotonic and vasodilator activities of MCI-154 revealed by the present study suggest that this agent would be an effective remedy for the treatment of heart failure."
03/01/1997 - "Thus a newly developed Ca2+ sensitizer, MCI-154, may be beneficial for the treatment of heart failure."
05/01/1993 - "Thus, MCI-154 may be useful in the management of heart failure with reduced coronary reserve."
06/01/1992 - "Thus, MCI-154 may be useful in the management of ischemic heart failure."
05/14/1999 - "To assess the long-term efficacy of a Ca2+ sensitizer MCI-154, 6-[4-(4'-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride trihydrate, on chronic heart failure, we studied the effects of the agent on the life span of cardiomyopathic hamsters of the BIO-14.6 strain. "
05/01/1993 - "The infusion of MCI-154 starting 20 min after ischemia improved the depressed segment shortening and LV dP/dtmax without increasing the ischemic zone MVO2 and regional myocardial blood flow. "
10/01/1996 - "We investigated the effect of a new Ca++ sensitizer, MCI-154, which is known to increase myofibrillar Ca++ sensitivity and maximal Ca(++)-activated force, on Ca++ transients and left ventricular (LV) function in indo-1-loaded Langendorff guinea plg hearts subjected to a reduction in coronary perfusion pressure from 80 to 40 mm Hg. During low-flow ischemia, LV contractility decreased by 50%, whereas systolic and diastolic indo-1 fluorescence ratios increased by 10%. "
10/01/1995 - "The alleviation of the postischemic contractile dysfunction by MCI-154 was augmented when the animals were treated with a bous injection of enalapril (0.3 mg/kg) 15 min before ischemia followed by an infusion of the drug (0.003 mg/kg/min). "
06/01/1992 - "Among the cardiotonic agents tested only MCI-154 attenuated myocardial acidosis during ischemia. "
10/01/1996 - "The treatment with MCI-154 (10(-10) to 10(-6) M) 15 min after ischemia effectively restored the depressed LV function with little effect on indo-1 ratio. "
11/01/1997 - "MCI-154 also improved the decline in maximal Ca2+-activated force by 20 mM Pi under acidic pH, but the acidosis did not further decrease the effect of 20 mM Pi. "
11/01/1997 - "Intracellular accumulation of inorganic phosphate (Pi) and intracellular acidosis, which occur in ischemic and hypoxic hearts, reduce the force of contraction by decreasing the responsiveness of contractile system to Ca2+. In the present study we investigated the effects of MCI-154, a Ca2+ sensitizer that can enhance crossbridge interaction, on the decline in maximal Ca2+-activated force by Pi or acidic pH in skinned fiber bundles of guinea pig hearts. "
04/01/1995 - "And 10(-4) mol/L of MCI-154 reversed the desensitization effect induced by either acidosis (pH 6.8), low temperature (15 degrees C), or the addition of inorganic phosphate (10 mmol/L).(ABSTRACT TRUNCATED AT 250 WORDS)"
06/01/1992 - "These results suggest that in addition to the attenuation of myocardial acidosis the positive inotropic action of MCI-154, presumably increasing the responses of myofilaments to Ca++, may be possibly responsible for the improvement of regional contractile function in the ischemic myocardium. "
06/01/1992 - "The degree of the attenuation of acidosis by MCI-154 was equivalent with that by ISDN. "
|4.||Septic Shock (Toxic Shock Syndrome)
12/01/2000 - "However, when skinned right ventricular papillary fibers from endotoxic shock rats were dealt with activating solutions containing 1 x 10(-5) M MCI-154, the Tmax was significantly increased, the tension-pCa relationship curve was shifted leftward. "
09/01/2000 - "MCI-154 exerts remarkable therapeutic effects on cardiac dysfunction after endotoxic shock."
09/01/2000 - "LVSP, IP, MC, and Lo were all markedly increased while HR did not obviously change and left ventricular end-diastolic pressure (LVEDP) was reduced markedly following MCI-154 administration in endotoxic shock rabbits. "
06/01/2000 - "It can be concluded that MCI-154 can exert significant therapeutic effects on cardiac dysfunction after endotoxic shock, for it improves cardiac function, dilates peripheral blood vessels, and slightly affects HR."
06/01/2000 - "On the contrary, LVSP, IP, MC, and Lo all were increased significantly while HR was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably following MCI-154 administration in endotoxic shock rabbits. "
|5.||Left Ventricular Dysfunction
03/01/1997 - "Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor."
01/10/1991 - "These results suggest that MCI-154 produces a more pronounced improvement of regional myocardial function than milrinone and dobutamine, presumably by increasing the responses of the contractile protein system to Ca2+. In this respect, MCI-154 would be of much benefit for the treatment of postischemic left ventricular dysfunction."
|8.||Cardiotonic Agents (Cardiac Stimulants)
|9.||salicylhydroxamic acid (SHAM)